You have found 31 entries. Starting with analyses of the most recently published documents, the list shows in orange the type of entry, year the original document was published (or if one of our own documents, the year last updated), and the type of file you will download when you click on the title. In blue is the document’s title followed by a brief description.
Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Re-order the list by the most recently added or updated entries or by the main topic addressed
If you have not found what you want you could:
Tab back to the Subject search page/tab to amend your original search.
Try a new search (clears your previous selection).
Instead try a free text search for documents which contain the words you specify.
Or try browsing back issues of the magazine or recent bulletins.
Documents are regularly added. Use the e-mail update service to monitor additions.
Try the information services provided by partner agencies.
Tried everything? E-mail the Findings editor for help by clicking on this logo
MATRIX CELL 2017 HTM file
Drug Matrix cell C1: Management/supervision: Reducing harm
Seminal and key studies on the role of management and supervision in reducing harm associated with illegal drug use.
REVIEW 2016 HTM file
Preventing opioid overdose deaths with take-home naloxone
To aid policymaking, experts commissioned by the European Union’s drug misuse monitoring centre review the evidence and offer guidance on the provision of the medication naloxone, which reverses the effects of drugs like heroin, helping to prevent overdoses becoming fatal.
DOCUMENT 2016 HTM file
Harm reduction database Wales: take home naloxone 2015–16
Report charting the roll-out of ‘take-home naloxone’ in Wales up to 2016, a harm-reduction measure implemented to prevent deaths involving opiate-type drugs.
In 2011 Scotland became the first country to fund a national policy of distributing the opiate-blocker naloxone to prevent deaths involving opiate-type drugs. According to this evaluation it did prevent deaths where the effect was most likely to be seen – in the weeks after release from prison.
How confident can we be that take-home naloxone programmes are effective without the ‘gold standard’ randomised trial? Judged against nine criteria for establishing the presumption of causality, evidence that the provision of naloxone reduces overdose-related deaths among opioid users.
From the USA’s professional society for clinicians and allied professionals in the field of addiction medicine, comprehensive recommendations on how doctors can use medications to treat addiction to heroin and other opioids.
Consolidates WHO guidance on HIV prevention, diagnosis, treatment and care for key populations including prisoners and people who inject drugs. Strongly advocates universal access of injectors to needle exchange and of dependent opioid users to indefinite, high dose methadone and buprenorphine maintenance.
DOCUMENT 2014 HTM file
Community management of opioid overdose
Experts convened by the World Health Organization judged the risk-benefit profile to be strongly in favour of naloxone distribution to prevent opiate overdose deaths, but also cautioned that this “does not address the underlying causes of opioid overdose”.
This real-world implementation of overdose education and nasal naloxone distribution in Massachusetts illustrates the life-saving potential of these programmes.
The first simulation of the cost-effectiveness of supplying naloxone kits to heroin users to enable them to prevent overdose deaths estimates that in the US context these programmes would be well within the range considered a cost-effective health intervention. Findings are likely to broadly apply to the UK, one weak link being whether drug users given the kits actually carry them around.
Select search results pagePREVIOUS | NEXT 1 2 3 4